Basilea Pharmaceutica valuation
CHF 66.40Change from previous close: −0.60%Absolute change: −CHF 0.40
Valuation
The P/E ratio is 16.7. The average price target of 4 analysts is CHF 107.78.
Data as of October 4, 2026
Valuation multiples
- Market cap
- CHF 827.78M
- Enterprise value
- CHF 738.91M
- P/E (trailing 12 months)
- 16.7
- Forward P/E
- 14.6
- PEG
- -0.08
- Price/book
- 5.10
- Price/sales
- 3.35
- EV/EBITDA
- 12.1
- EV/revenue
- 2.99
Profitability and growth
- Gross margin
- 38.5%
- Operating margin
- 26.9%
- Net margin
- 21.2%
- ROE
- 39.5%
- ROA
- 13.7%
- Revenue growth (year over year)
- 14.5%
- Earnings growth (year over year)
- 64.4%
Financial health
- Total cash
- CHF 173.05M
- Total debt
- CHF 83.44M
- Debt/equity
- 0.51
- Current ratio
- 6.60
- Quick ratio
- 5.81
Dividends
- Payout ratio
- 0.0%
- Ex-dividend date
- April 11, 2013
Analysts and estimates
- Average price target
- CHF 107.78
- Median price target
- CHF 115.00
- High price target
- CHF 126.10
- Low price target
- CHF 75.00
- Analysts with a price target
- 4
- Forward EPS
- CHF 4.58
- EPS estimate, current year
- CHF 4.31
Shares and trading
- Beta
- 0.43
- Average volume
- 41.5K
- Shares outstanding
- 12.39M
- Float
- 11.31M
- Institutional ownership
- 30.4%
- Insider ownership
- 0.6%